Tychan Pte Ltd. is a privately owned biotechnology company headquartered in Singapore. The company was established by Ram Sasisekharan and Eng Eong Ooi and is currently led by CEO Randall E. Woods. Tychan's mission is to develop innovative treatments for emerging infections and make them accessible to those in need. The company collaborates closely with regulatory authorities to expedite the transition from non-clinical research to clinical trials for emerging pathogens. Tychan was founded by experts in biologics development and the biology of acute viral infections and is backed by Temasek Holdings.

Tags

Infectious Diseases

Other Diseases

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Biological products	1

Drugs associated with Tychan Pte Ltd.

TY-014

Target-

Mechanism

Immunostimulants

Active Org.

Tychan Pte Ltd.

Originator Org.

Tychan Pte Ltd.

Active Indication

Yellow Fever

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

Tyzivumab

Target

ZIKV E protein

Mechanism

ZIKV E protein inhibitors

Active Org.-

Originator Org.

Tychan Pte Ltd.

Active Indication-

Inactive Indication

Zika Virus Infection

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date-

TY-027

Target

SARS-CoV-2 S protein

Mechanism

SARS-CoV-2 S protein modulators

Active Org.-

Originator Org.

Tychan Pte Ltd.

Active Indication-

Inactive Indication

COVID-19

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Tychan Pte Ltd.

NCT04649515

/ TerminatedPhase 3

Phase 3 Multi-Site, Randomised, Placebo Controlled, Double Blind, Single Dose Study of TY027 for Early Treatment of COVID-19

The emergence & rapid spread of the coronavirus disease 2019 (COVID-19) since December 2019 across 188 countries globally has become a major public health crisis. COVID-19 was declared a pandemic by the World Health Organisation on 11 March 2020. To date, tens of millions of cases have been reported and over 3% of these cases have died. COVID-19 is an acute respiratory disease caused by the novel SARS-CoV-2 virus from the Betacoronavirus genus, just like SARS-CoV and MERS-CoV. SARS-CoV-2 is primarily transmitted person-to-person through respiratory droplets/close contact. Fomite transmission has also been shown as a transmission route. Common respiratory symptoms such as fever, sore throat, cough & shortness of breath, may appear 2 - 14 days after exposure. About 20% of infected cases progress to severe disease resulting in an estimated 2 - 5% mortality rate. With the unrelenting increase in cases being reported worldwide, there is thus an urgent need for therapeutics to be developed to treat disease & reduce further transmission in order to disrupt the ongoing pandemic.
To date, there are no specific proven antiviral treatment to prevent disease progression from mild to severe respiratory dysfunction among COVID-19 patients. Supportive care is recommended for symptom relief & for severe cases. Numerous vaccine candidates against SARS-CoV-2 are under development. Tychan's TY027, a fully engineered human IgG, is one of the first few biologics in the world, specifically targeting SARS-CoV-2, to enter human clinical trials. Preliminary data from our phase 1 healthy volunteer trial (SCT-001; ClinicalTrials.gov Identifier NCT04429529) reveals that TY027 is safe & well-tolerated up to 20 mg/kg tested. A total of 10 adverse events (AEs) were observed, all were of mild in intensity with none resulting in subject withdrawal from the study. There were no serious adverse events & no clinically relevant trends in mean clinical laboratory, physical examinations, vital signs or ECG results were observed. Pharmacokinetic profile of subjects across dose cohorts 1 - 4, up to Day 14, were comparable to those typical of human IgG1 antibody with serum concentrations declining in a biphasic manner. Exposure of TY027, based on Cmax, increased in a linear & generally dose proportional manner. It is anticipated that TY027, when administered to acutely infected COVID-19 patients, could reduce disease severity. It may potentially also be used as a prophylaxis against COVID-19 amongst high risk contacts.

Start Date04 Dec 2020

Sponsor / Collaborator

Tychan Pte Ltd.

NCT04429529

/ CompletedPhase 1

Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers

The emergence and rapid spread of the coronavirus disease 2019 (COVID-19) since December 2019 across 188 countries globally has become a major public health crisis. COVID-19 was declared a pandemic by the World Health Organisation (WHO) on the 11th March 2020. To date, more than 14,000,000 cases and 600,000 deaths have been reported. COVID-19 is an acute respiratory disease caused by the novel SARS-CoV-2 virus from the Betacoronavirus genus, just like SARS-CoV and MERS-CoV. SARS-CoV-2 is primarily transmitted person-to-person through respiratory droplets or close contact. Fomite transmission has also been implicated as a transmission route. Common respiratory symptoms such as fever, sore throat, cough and shortness of breath, may appear 2 - 14 days after exposure. About 20% of infected cases progress to severe disease resulting in an estimated 2 - 5% mortality reported. With the unrelenting increase in cases being reported worldwide, there is thus an urgent need for therapeutics to be developed and used to disrupt the ongoing pandemic.
To date, there is no specific proven antiviral treatment for COVID-19. Supportive care is recommended for symptom relief and for severe cases, organ support is critical for optimal outcome. Numerous vaccine candidates against SARS-CoV-2 are under development and a couple have entered Phase 1 clinical trials. Remdesivir, a nucleotide analog, developed by Gilead Sciences as a treatment for Ebola virus disease is currently being repurposed and undergoing multiple clinical trials to evaluate safety and efficacy in COVID-19 patients. In a preliminary study, convalescent plasma containing neutralizing antibodies against SARS-CoV-2 has also been experimentally administered in critically ill COVID-19 patients with promising results. Donor plasma used was rich in virus specific IgG and IgM antibodies as determined by ELISA. Within days of convalescent plasma treatment, patients showed decrease in viral load (via qRT-PCR), as well as improved clinical status being observed. Tychan's TY027 will be the first biologics in the world, specifically targeting SARS-CoV-2, to enter human clinical trials. It is anticipated that a SARS-COV-2 specific monoclonal antibody therapeutic administered to acutely infected patients could reduce disease severity as well as prevent transmission by reducing viral load and viral shedding. It could also be used as prophylaxis against COVID-19 amongst high risk contacts.

Start Date09 Jun 2020

Sponsor / Collaborator

Tychan Pte Ltd.

NCT03776695

/ WithdrawnPhase 1

Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients

Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti. ZIKV is a growing public health problem, rapidly spreading throughout the continents since the first epidemic was reported in the French Polynesian islands.
Currently, there are several ZIKV vaccine candidates in clinical trials. However, no ZIKV therapy (biologic or small molecule) has advanced to clinical trials. Tyzivumab will be the first therapeutic in the world, specifically targeting ZIKV, to enter clinical trials.
This is a Phase 1, time-lagged, parallel-group, randomized, placebo-controlled, single-blind, single ascending dose, Tyzivumab, ZIKV monoclonal antibody (mAb), study to be conducted in ZIKV polymerase chain reaction (PCR) positive patients.
Tyzivumab will be administered once through single IV infusion over 30 minutes. Total duration of study participation is estimated at approximately 85 days from the date of screening. Post-trial monitoring through weekly telephone calls will continue from Day 85 post-dose onwards for another three (3) more months.
The main objective of this study is to evaluate the safety of Tyzivumab in acutely infected adult patients. Assessment of time taken to achieve negative ZIKV isolation from acute ZIKV infected subjects' blood will be the study's secondary objectives.

Start Date09 Oct 2018

Sponsor / Collaborator

Tychan Pte Ltd.

[+2]

100 Clinical Results associated with Tychan Pte Ltd.

0 Patents (Medical) associated with Tychan Pte Ltd.

Literatures (Medical) associated with Tychan Pte Ltd.

01 Aug 2021·Antiviral ResearchQ2 · MEDICINE

An antibody engineering platform using amino acid networks: A case study in development of antiviral therapeutics

Q2 · MEDICINE

Article

Author: Ghafar, Nahdiyah Abdul ; Raman, Rahul ; Lee, Debbie Ching Ping ; Budigi, Yadunanda

We present here a case study of an antibody-engineering platform that selects, modifies, and assembles antibody parts to construct novel antibodies. A salient feature of this platform includes the role of amino acid networks in optimizing framework regions (FRs) and complementarity determining regions (CDRs) to engineer new antibodies with desired structure-function relationships. The details of this approach are described in the context of its utility in engineering ZAb_FLEP, a potent anti-Zika virus antibody. ZAb_FLEP comprises of distinct parts, including heavy chain and light chain FRs and CDRs, with engineered features such as loop lengths and optimal epitope-paratope contacts. We demonstrate, with different test antibodies derived from different FR-CDR combinations, that despite these test antibodies sharing high overall sequence similarity, they yield diverse functional readouts. Furthermore, we show that strategies relying on one dimensional sequence similarity-based analyses of antibodies miss important structural nuances of the FR-CDR relationship, which is effectively addressed by the amino acid networks approach of this platform.

Nature CommunicationsQ1 · CROSS-FIELD

Allosteric pyruvate kinase-based “logic gate” synergistically senses energy and sugar levels in Mycobacterium tuberculosis

Q1 · CROSS-FIELD

ArticleOA

Author: Cui, Liang ; Fothergill-Gilmore, Linda A ; Sahili, Abbas El ; Dedon, Peter C ; Goh, Boon Chong ; Cai, Qixu ; Lescar, Julien ; Ho, Peiying ; Chionh, Yok Hian ; Zhong, Wenhe ; Walkinshaw, Malcolm D ; Yuan, Meng

AbstractPyruvate kinase (PYK) is an essential glycolytic enzyme that controls glycolytic flux and is critical for ATP production in all organisms, with tight regulation by multiple metabolites. Yet the allosteric mechanisms governing PYK activity in bacterial pathogens are poorly understood. Here we report biochemical, structural and metabolomic evidence that Mycobacterium tuberculosis (Mtb) PYK uses AMP and glucose-6-phosphate (G6P) as synergistic allosteric activators that function as a molecular “OR logic gate” to tightly regulate energy and glucose metabolism. G6P was found to bind to a previously unknown site adjacent to the canonical site for AMP. Kinetic data and structural network analysis further show that AMP and G6P work synergistically as allosteric activators. Importantly, metabolome profiling in the Mtb surrogate, Mycobacterium bovis BCG, reveals significant changes in AMP and G6P levels during nutrient deprivation, which provides insights into how a PYK OR gate would function during the stress of Mtb infection.

News (Medical) associated with Tychan Pte Ltd.

10 Jun 2020

·www.biospace.com

Biopharma Update on the Novel Coronavirus: June 10

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020. News information is not all-inclusive and updates will now be published on Mondays, Wednesdays and Fridays. FDA Actions Temporary Policy on Prescription Drug Marketing Act Requirements : The FDA issued guidance addressing questions concerning prescription drug sample distribution under the Prescription Drug Marketing Act of 1987 (PDMA) during the COVID-19 pandemic. Ventilators: The FDA added the BioMedInnovations SuppleVent Ventilator to the list of authorized ventilators. Warning Letter: The FDA issued a warning letter to organic-beauty-recipes.com for selling fraudulent COVID-19 products. Diagnostics Update : The FDA has worked with more than 400 test developers who have submitted or plan to submit EUA requests to detect COVID-19. Also, 128 individual EUAs have been issued, which includes 108 molecular tests, 19 antibody tests and 1 antigen test. Diagnostics Illumina indicated the U.S. Food and Drug Administration (FDA) issued an EUA for the Illumina COVIDSeq™ Test, a sequencing-based, in vitro diagnostic (IVD) workflow for the detection of SARS-CoV-2. Avacta Group announced a BAMS (bead-assisted mass spectrometry) diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix, an detect the coronavirus spike protein in model samples in the concentration range appropriate for a clinical diagnostic test. The BAMS assay uses the Affimer reagents specific to the SARS-COV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry. Dark Daily , a firm focused on clinical diagnostics, published an article discussing how the COVID-19 pandemic is affecting clinical laboratory specimen transportation. Some of the challenges include limited officer hours, closed physician practices, and requiring couriers to check for symptoms on healthcare campuses. Vermillion ’s wholly-owned subsidiary ASPIRA Labs completed laboratory validation of the Roche Elecsys Anti-SARS-CoV-2 antibody test for antibodies against COVID-19. The test and other biomarkers will be used on the ASPIRA pelvic mass assessment pre-surgery workup. Testing Therapies, Antivirals and Vaccines In an interview this morning with CNN, Dr. Anthony Fauci said the government will help finance Phase III studies of three COVID-19 vaccine candidates. The vaccine candidates that the government will subsidize the late-stage trial are under development by Moderna , AstraZeneca and the Jenner Institute of Oxford , and Johnson & Johnson . Past vaccine failures may reduce COVID-19 vaccination rates . With more than 130 COVID-19 vaccines in development around the world, many of them are bound to fail. When they do, will that erode the public trust in the vaccines that are approved? The answer largely depends on where in the development cycle the vaccines fail and the scope of their failure. Fulcrum Therapeutics announced it has submitted an investigational new drug (IND) application to evaluate losmapimod as a potential treatment for patients with COVID-19. Fulcrum is preparing to start a Phase III trial. Losmapimod is a p38 inhibitor currently being studied in a Phase 2b clinical trial in patients with facioscapulohumeral muscular dystrophy. Inhibition of the p38 MAPK pathway may play a role in treating COVID-19-related symptoms. IGY Life Sciences and MMS Holdings will collaborate to advance the development of IgY-110, an anti-CoV-2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed, the companies said. The nasal spray therapeutic is intended to treat those currently infected with COVID-19 by controlling and blocking the spread of coronavirus. India’s Panacea Biotech and Refana Inc. USA forged an agreement to develop a COVID-19 vaccine. Tychan announced it is initiating Phase I clinical trials to evaluate TY027, a novel monoclonal antibody (mAb) that specifically targets SARS-CoV-2. The trial is expected to take only about six weeks. Kalytera Therapeutics announced proof-of-concept data for R-107, its liquid nitric oxide donor, to treat pulmonary arterial hypertension (PAH) in COVID-19 patients with acute respiratory distress syndrome (ARDS). Eli Lilly launched a Phase I study of its second COVID-19 antibody treatment with partner Junshi Biosciences . The antibody, JS016 is the company’s second neutralizing antibody to begin trials, following LY-CoV555. Other Industry News The novel coronavirus that has swept across the globe over the past few months infecting millions of people remains a mystery in many ways due to the complexity of the disease. That was the sentiment expressed by Dr. Anthony Fauci , the director of the National Institute of Allergy & Infectious Diseases (NIAID) , during a one-on-one interview with Michelle McMurry-Heath, the new chief executive officer of Biotechnology Innovation Organization (BIO) .

Phase 2VaccinePhase 1

100 Deals associated with Tychan Pte Ltd.

100 Translational Medicine associated with Tychan Pte Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TY-014	Yellow Fever More	Phase 1
TY-027 ( SARS-CoV-2 S protein )	COVID-19 More	Discontinued
Tyzivumab ( ZIKV E protein )	Zika Virus Infection More	Discontinued

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis